TY - CHAP M1 - Book, Section TI - Chapter 39. Male Sexual Dysfunction A1 - Lue, Tom f. A2 - McAninch, Jack W. A2 - Lue, Tom F. PY - 2013 T2 - Smith & Tanagho's General Urology, 18e AB - It is estimated that more than half of men aged 40–70 years in the United States are unable to attain or maintain a penile erection sufficient for satisfactory sexual performance. Advances in pharmacologic therapy for erectile dysfunction (ED), coupled with a better understanding of male sexual dysfunction, have resulted in greater numbers of patients seeking care for sexual concerns. Oral phosphodiesterase type-5 inhibitors (PDE-5Is) have emerged as the preferred first-line treatment of ED worldwide due to their efficacy, ease of use, and patient safety. Erectile function can now be evaluated by the response to these agents at home or intracavernous injection (ICI) of vasoactive agents in the office, and improved diagnostic tests can differentiate among types of impotence. Patient satisfaction with penile prostheses is high, as the latest generation of devices is more sophisticated and durable than ever. Current treatments continue to evolve and new therapies such as stem cells and gene therapies may represent the next generation of more physiologic and disease-specific solutions to various types of ED (Bahk et al, 2010; Lin et al, 2009; Melman et al, 2007). SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/29 UR - accesssurgery.mhmedical.com/content.aspx?aid=56950308 ER -